The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies

Abstract

Graphical Abstract Graphical Abstract Panel A. Primary endpoint of DELIVER [cardiovascular (CV) death or heart failure (HF) hospitalization] in the entire population (left) and in the population with LVEF 60. Panel B. A pooled analysis of patients enrolled in the DAPA-HF and DELIVER trials reveals a consistent benefit of dapagliflozin on the primary endpoint (CV death or HF hospitalization) across the entire spectrum of LVEF, with no signs of attenuation of the effect in the higher LVEF range. Panel C. Effect of acetazolamide on congestion in the ADVOR trial. From Day 1 onwards, the use of acetazolamide on top of regular loop diuretics resulted in accelerated decongestion. Panel D. KaplanMeier estimates of all-cause mortality or HF hospitalization for patients receiving PCI or optimal medical therapy in the REVIVED trial. LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.

Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice

“…Luckily, in 2022, three seminal trials on medical treatments to relieve congestion additive to loop diuretics have been published. 8 …”

(Commentary to the article The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies)

“…Jak uvádějí autoři v úvodu článku, 1 rok 2022 byl z pohledu srdečního selhání ,,vzrušující". Byly totiž publikovány výsledky hned několika zásadních prací, které ovlivní budoucí doporučení odborných společností a klinickou praxi v péči o pacienty se srdečním selháním.…”